Tesamorelin Lyophilised Peptide
Tesamorelin is a synthetic 44-residue analogue of human growth hormone-releasing factor (GHRH 1-44) carrying an N-terminal trans-3-hexenoyl group. It is classified as a growth hormone-releasing factor analogue and has been studied in HIV-associated abdominal fat accumulation. Tesamorelin is supplied as a lyophilised (freeze-dried) powder in a sealed vial, in 10 mg and 20 mg sizes, priced RM 165–255. No certificate of analysis has been published for the batch on sale yet, so no purity figure is claimed on this page. Ships within 2 working days of payment. Sold for laboratory research use only, not for human or veterinary use.
Research use only. Sold for laboratory research only. Not for human or veterinary use, not for consumption, and not a medicine, food or cosmetic.
- Ships within 2 working days of payment.
- Free shipping across Malaysia.
- Pay by FPX online banking.
Certificates of analysis
No certificate of analysis has been published for the batch on sale yet, so this page makes no purity claim. Each certificate will name the testing laboratory, the batch, the test date and the method.
Tesamorelin specifications
| Also known as | TH9507, Egrifta SV, Egrifta WR, N-hexanoyl-Tyr1 hGRF(1-44) |
|---|---|
| Form | Lyophilised (freeze-dried) powder in a sealed vial |
| Sizes | 10 mg · 20 mg |
| CAS number | 218949-48-5 |
| Molecular formula | C221H366N72O67S |
| Molecular weight | 5,135.9 g/mol |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2, with a (3E)-hex-3-enoyl group on the N-terminal Tyr (44 residues) |
| PubChem | CID 16137828 |
| Storage (sealed) | -20 °C (supplier specification; stability stated as ≥4 years) |
| Storage (reconstituted) | aqueous solutions not recommended for storage beyond one day (supplier insert) |
What research says about Tesamorelin
Tesamorelin is a synthetic 44-residue analogue of human growth hormone-releasing factor (GHRH 1-44) carrying an N-terminal trans-3-hexenoyl group. It is classified as a growth hormone-releasing factor analogue and has been studied in HIV-associated abdominal fat accumulation.
Acts as a GHRH analogue that stimulates pituitary growth hormone release; in the pivotal trial it was accompanied by a rise in IGF-I (Falutz 2007).
Approved in the US (FDA) as Egrifta SV and Egrifta WR (Theratechnologies) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, per DailyMed labels.
Cited studies
-
In a 26-week trial in 412 patients with HIV, visceral adipose tissue changed by -15.2% with tesamorelin versus +5.0% with placebo, and IGF-I rose by 81.0% versus a 5.0% fall.
Metabolic effects of a growth hormone-releasing factor in patients with HIV.. New England Journal of Medicine, 2007. doi:10.1056/NEJMoa072375 · PubMed 18057338
-
In a 6-month randomised trial of 50 patients, tesamorelin was associated with reduced visceral adipose tissue and liver fat compared with placebo; fasting glucose rose transiently at 2 weeks.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.. JAMA, 2014. doi:10.1001/jama.2014.8334 · PubMed 25038357
-
In a pooled analysis of two phase 3 trials (806 patients), visceral-fat responders showed larger reductions in ALT and AST than non-responders at 26 weeks.
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.. AIDS, 2017. doi:10.1097/QAD.0000000000001614 · PubMed 28832410
Handling and storage
- Sealed vial
- -20 °C (supplier specification; stability stated as ≥4 years)
- After reconstitution
- aqueous solutions not recommended for storage beyond one day (supplier insert)
Shipping, returns and payment
Dispatch. Ships within 2 working days of payment.
Shipping. Free shipping across Malaysia. Peninsular Malaysia 1–4 working days; Sabah, Sarawak and Labuan 3–7 working days.
Returns. No change-of-mind returns; a wrong or damaged item is replaced or refunded. Nothing here affects your rights under the Consumer Protection Act 1999.
Payment. FPX online banking.
Questions
- Is there a certificate of analysis for Tesamorelin?
Not yet for the batch on sale. When one is published it appears in the certificates table on this page with the laboratory, batch, test date, method and result. See how to read a certificate of analysis.
- How is Tesamorelin stored?
Sealed: -20 °C (supplier specification; stability stated as ≥4 years). After reconstitution: aqueous solutions not recommended for storage beyond one day (supplier insert). These are supplier figures, cited in the handling section.
More about Tesamorelin
-
Research summary
Tesamorelin: what the published research reports
Tesamorelin is a stabilised analogue of growth hormone-releasing hormone that stimulates growth hormone release from the pituitary. Its evidence comes mainly from randomised trials in people with HIV, where it has an approved use in the United States.
